Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates

Core Viewpoint - Co-Diagnostics, Inc. reported a quarterly loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a loss of $0.25, indicating an earnings surprise of +8.00% [1] Financial Performance - The company posted revenues of $0.16 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 45.67%, and a significant decline from $2.66 million in the same quarter last year [2] - Over the last four quarters, Co-Diagnostics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $0.3 million, and for the current fiscal year, it is -$0.68 on revenues of $0.95 million [7] Stock Performance - Co-Diagnostics shares have declined approximately 64.9% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]